Registration Now Open For Tribe Public’s Webinar Event "Addressing The Increasing Demand For Rare Cannabinoids" Featuring InMed’s Management Team On January 6, 2022
December 30 2021 - 7:30AM
InMed Pharmaceuticals Inc. (“InMed” or the
“Company”) (Nasdaq: INM), a leader in the development,
manufacturing and commercialization of rare cannabinoids, announces
that InMed’s CEO Eric A. Adams, Shane Johnson, SVP and General
Manager of BayMedica and Chris Meiering, VP of Commercial
Operations will present at Tribe Public’s Webinar Presentation and
Q&A Event titled
"Addressing The Increasing Demand For
Rare Cannabinoids." The Event is scheduled to begin at 8am
Pacific/11am Eastern on January 6, 2022.
To register to join the complimentary, ZOOM
webinar-based event, please visit Tribe Public LLC at
INM22.TribePublic.com. Once registered, participants may begin
forwarding their questions for InMed & BayMedica’s management
to Tribe Public at research@tribepublic.com or share
their questions via the ZOOM chat feature during the event. Tribe
Public’s Managing Member, John F. Heerdink, Jr., will host the
event and relay questions to management.
About InMed: InMed
Pharmaceuticals is a global leader in the development,
manufacturing and commercialization of rare cannabinoids. Together
with its subsidiary, BayMedica LLC, the Company has unparalleled
cannabinoid manufacturing capabilities to serve a spectrum of
consumer markets, including pharmaceutical and health and wellness.
InMed is a clinical-stage company developing a pipeline of rare
cannabinoid therapeutics and dedicated to delivering new treatment
alternatives to patients that may benefit from cannabinoid-based
pharmaceutical drugs. For more information,
visit www.inmedpharma.com and www.baymedica.com.
About Tribe Public LLCTribe
Public LLC is a San Francisco, CA-based organization that hosts
complimentary worldwide webinar & meeting events in the U.S.
Tribe’s events focus on issues that the Tribe’s members care about
with an emphasis on hosting management teams and experts from
publicly traded companies from all sectors & financial
organizations that are seeking to increase awareness of their
products, progress, and plans. Tribe members primarily include
Institutions, Family Offices, Portfolio Managers, Registered
Investment Advisors, Accredited Investors, Sell Side Analysts, and
members of media. Tribe Members are encouraged to express their
interest in speakers at the Tribe Public website via the Tribe’s
FREE “Wish List” process. Visit Tribe Public’s
Website http://www.tribepublic.com/ to join the Tribe and
express your interests today.
Investor Contact: Colin
ClancySenior Director, Investor RelationsT: +1.604.416.0999E:
cclancy@inmedpharma.com
Cautionary Note Regarding
Forward-Looking Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking information") within the meaning of applicable
securities laws. Forward-looking information is based on
management's current expectations and beliefs and is subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about: participating in the January
6, 2022 Tribe Public’s Webinar; being a global leader in the
development, manufacturing and commercialization of rare
cannabinoids; serving a spectrum of consumer markets, including
pharmaceutical and health and wellness; and, developing a pipeline
of rare cannabinoid therapeutics and dedicated to delivering new
treatment alternatives to patients that may benefit from
cannabinoid-based pharmaceutical drugs.
With respect to the forward-looking information
contained in this news release, InMed has made numerous
assumptions. While InMed considers these assumptions to be
reasonable, these assumptions are inherently subject to significant
business, economic, competitive, market and social uncertainties
and contingencies.
Additionally, there are known and unknown risk
factors which could cause InMed's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking information contained herein. A complete discussion
of the risks and uncertainties facing InMed’s stand-alone business
is disclosed in InMed’s Annual Report on Form 10-K and other
filings with the Security and Exchange Commission on
www.sec.gov.
All forward-looking information herein is
qualified in its entirety by this cautionary statement, and InMed
disclaims any obligation to revise or update any such
forward-looking information or to publicly announce the result of
any revisions to any of the forward-looking information contained
herein to reflect future results, events or developments, except as
required by law.
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Aug 2024 to Sep 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Sep 2023 to Sep 2024